HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Stopped early · Phase 4

Conditions studied: Metastatic Melanoma

In brief

Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy. Treatment Arm 1: "HD IL-2 first, then ipilimumab" Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab. Treatment Arm 2: Ipilimumab first then HD IL-2 Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

Key facts

Study ID

NCT01856023

Run by

Clinigen, Inc.

People needed

29

Starts

2013-05-01

Expected to finish

2015-07-01

Last updated by the study team

2023-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients 18 years or older
• Confirmed and measurable metastatic melanoma with at least one measurable lesion for evaluation of response
• Meets the requirements for HD IL-2 therapy per Institutional guidelines
• Meets the requirements for ipilimumab therapy per Institutional guidelines
• Treatment naïve or has received only one systemic therapy apart from adjuvant therapy.
• At least 4 weeks since last adjuvant therapy or other cancer treatment
• Willing and able to give informed consent and participate in study procedures as described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will also be asked to participate in the 10PLK13 PROCLAIM registry study.

You may not qualify if…

• Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis
• Pregnant, nursing or planning to become pregnant
• Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI at least 6 weeks after definitive therapy are acceptable.)
• Received prior ipilimumab therapy (Prior Adjuvant Ipilimumab and Adjuvant Interferon are permitted with a minimum 4 week washout)
• Received prior HD IL-2 therapy.
• Received investigational drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical studies, including the 10PLK13 PROCLAIM registry study.
• Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.

Where it is running

• The University of Arizona Cancer Center — Tucson, Arizona, United States
• Moores UCSD Cancer Center — La Jolla, California, United States
• MSMC Research Program — Miami Beach, Florida, United States
• Oncology Specialists, SC — Park Ridge, Illinois, United States
• University of Iowa Hospitals & Clinics — Iowa City, Iowa, United States
• Johns Hopkins Medicine — Lutherville, Maryland, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Nebraska Cancer Specialists, Midwest Cancer Center - Legacy — Omaha, Nebraska, United States
• Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Duke University Health System — Durham, North Carolina, United States
• The Christ Hospital — Cincinnati, Ohio, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.